Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial

S.S. Lund*, L. Tarnow, C.D.A. Stehouwer, C.G. Schalkwijk, M. Frandsen, U.M. Smidt, O.F. Pedersen, H.H. Parving, A. Vaag

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Aim: Metformin is the 'drug-of-first-choice' in obese patients with type 2 diabetes mellitus (T2DM) due to its antihyperglycaemic and cardiovascular protective potentials. In non-obese patients with T2DM, insulin secretagogues are empirically used as first choice. In this investigator-initiated trial, we evaluated the effect of metformin vs. an insulin secretagogue, repaglinide on glycaemic regulation and markers of inflammation and insulin sensitivity in non-obese patients with T2DM. Methods: A single-centre, double-masked, double-dummy, crossover study during 2 x 4 months involved 96 non-obese (body mass index
Original languageEnglish
Pages (from-to)394-407
JournalDiabetes Obesity & Metabolism
Volume9 (3)
Publication statusPublished - 1 Jan 2007

Cite this